PARTNERSHIP OPPORTUNITIES
Want to Become the Go-To Provider for Drug Developers Leading the Covalency Renaissance?
Capitalizing on the breakthroughs of the covalent KRAS G12C inhibitors, the momentum to deploy covalency as a primary drug discovery effort continues to grow, drawing in new and distinguished biopharma. As they gear-up to develop first-in-class covalent drugs for previously hard-to-drug targets, they need support in Assay Development, Covalent Library and Screening Capabilities, Computational Platforms, Chemoproteomics, Biophysics Characterization solutions and Pre-clinical and Clinical services.
The 2nd Covalent Drug Discovery & Development Summit serves as a central hub to showcase your expertise and benchmark your brand as a key solutions provider and thought-leader, through our bespoke commercial packages.
Benefit from Market Intelligence:
Hear how and where biopharma are searching for services and solutions to facilitate their efforts to develop, validate and clinically progress novel covalent inhibitors, monovalent, heterobifunctionals, and biologics
Showcase Your World-Class Solutions:
Differentiate your discovery and pre-clinical services from other solution providers to stand out amongst your competition
Generate Commercial Collaborations:
Meet prospective clients during speed networking breaks and informal networking receptions
Who Will You Meet?
If you offer relevant services and would like to showcase your solutions within this booming covalency space, contact us to discuss a bespoke commercial package to promote your company at this year’s 2nd Covalent Drug Discovery & Development Summit.
For more information, email sponsor@hansonwade.com or download the full event guide here.
